The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and...

Seres parlayed lessons learned from the failed Phase II trial of SER-109 to treat recurrent C. difficile infection into a Phase III win through improved patient selection and higher dosing. Seres Therapeutics Inc. (NASDAQ:MCRB) added...

Chi-Med raises $100M private placement Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...

With $60 million in a new series C round, Alladapt will test its broad-spectrum immunotherapy approach to treat a broad swath of food allergies in its first clinical trial beginning this year. Gurnet Point Capital...

$200M for Aimmune as it expands allergy pipeline Nestlé Health Science made a $200 million equity investment in Aimmune Therapeutics Inc. (NASDAQ:AIMT), giving it a 19.9% stake in the allergy company based on its outstanding...

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ. Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of endogenous...

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...